JP2017538750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538750A5 JP2017538750A5 JP2017532912A JP2017532912A JP2017538750A5 JP 2017538750 A5 JP2017538750 A5 JP 2017538750A5 JP 2017532912 A JP2017532912 A JP 2017532912A JP 2017532912 A JP2017532912 A JP 2017532912A JP 2017538750 A5 JP2017538750 A5 JP 2017538750A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- sulfonamide
- benzimidazole
- methylcyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422771 | 2014-12-19 | ||
| GB1422771.4 | 2014-12-19 | ||
| PCT/GB2015/054064 WO2016097749A1 (en) | 2014-12-19 | 2015-12-17 | Parg inhibitory compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538750A JP2017538750A (ja) | 2017-12-28 |
| JP2017538750A5 true JP2017538750A5 (enExample) | 2019-02-07 |
| JP6673920B2 JP6673920B2 (ja) | 2020-03-25 |
Family
ID=54937310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532912A Active JP6673920B2 (ja) | 2014-12-19 | 2015-12-17 | Ｐａｒｇ阻害化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10508086B2 (enExample) |
| EP (2) | EP3233845B1 (enExample) |
| JP (1) | JP6673920B2 (enExample) |
| KR (1) | KR102682782B1 (enExample) |
| CN (2) | CN107295799B (enExample) |
| AU (1) | AU2015365602B2 (enExample) |
| BR (1) | BR112017012707B1 (enExample) |
| CA (1) | CA2969298C (enExample) |
| ES (1) | ES2886471T3 (enExample) |
| IL (1) | IL252745B (enExample) |
| MA (1) | MA41179A (enExample) |
| MX (1) | MX380901B (enExample) |
| RU (1) | RU2017125520A (enExample) |
| SG (1) | SG11201704843QA (enExample) |
| WO (1) | WO2016097749A1 (enExample) |
| ZA (1) | ZA201704383B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| EP3947351A4 (en) | 2019-03-29 | 2022-12-07 | Board of Regents, The University of Texas System | SMALL MOLECULAR PARG INHIBITORS AND METHODS OF USE |
| EP4031249A1 (en) * | 2019-09-20 | 2022-07-27 | Ideaya Biosciences, Inc. | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
| WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| EP4401721A4 (en) | 2021-10-17 | 2025-10-15 | Univ Of South Alabama Foundation For Research And Commercialization | CANCER TREATMENT |
| CA3251360A1 (en) | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | PARG INHIBITORS |
| WO2023165571A1 (zh) * | 2022-03-04 | 2023-09-07 | 上海璎黎药业有限公司 | 一种含五元杂芳环结构化合物、其药物组合物及应用 |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| CR20240391A (es) * | 2022-03-23 | 2024-11-05 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg |
| CN114685283B (zh) * | 2022-04-06 | 2024-02-27 | 南京艾康生物科技有限公司 | 一种1-(氟甲基)环丙胺盐酸盐的制备方法 |
| WO2023205914A1 (en) * | 2022-04-28 | 2023-11-02 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| CN117157299B (zh) * | 2022-04-28 | 2024-05-28 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| CA3251429A1 (en) | 2022-05-17 | 2023-11-23 | 858 Therapeutics, Inc. | PARG INHIBITORS |
| AU2023297713A1 (en) * | 2022-06-29 | 2025-02-13 | Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. | Five-membered and six-membered nitrogen-containing compound, and intermediate, preparation method and use thereof |
| EP4559912A1 (en) * | 2022-07-19 | 2025-05-28 | Evopoint Biosciences Co., Ltd. | Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| AU2023355735A1 (en) | 2022-10-03 | 2025-04-03 | Forx Therapeutics Ag | Parg inhibitory compound |
| WO2024080792A1 (en) * | 2022-10-13 | 2024-04-18 | Hanmi Pharm. Co., Ltd. | Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same |
| WO2024120519A1 (zh) * | 2022-12-09 | 2024-06-13 | 捷思英达控股有限公司 | Tead抑制剂、其制备方法和在医学上的应用 |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2024222842A1 (en) * | 2023-04-27 | 2024-10-31 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| WO2024243304A2 (en) * | 2023-05-23 | 2024-11-28 | Quantx Biosciences Us, Inc. | Bicyclic heteroaryl compounds |
| WO2024254990A1 (zh) * | 2023-06-16 | 2024-12-19 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025035108A2 (en) * | 2023-08-10 | 2025-02-13 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
| WO2026022150A1 (en) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Parg inhibitory compounds |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1157858A (en) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Quinazoline derivatives |
| DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AU1065400A (en) | 1998-11-12 | 2000-06-05 | Bae Systems Electronics Limited | Scanning of electromagnetic beams |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05708B1 (et) | 1999-02-10 | 2014-04-15 | Astrazeneca Ab | Kinasoliini derivaat angiogeneesi inhibiitorina ja selle kasutamine |
| DE19927415A1 (de) * | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| JP2003535078A (ja) | 2000-05-31 | 2003-11-25 | アストラゼネカ アクチボラグ | 血管損傷活性のあるインドール誘導体 |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| CA2411160A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| ES2322602T3 (es) | 2004-02-24 | 2009-06-23 | Japan Tobacco, Inc. | Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc. |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| MXPA06010852A (es) | 2004-03-25 | 2007-01-16 | Memory Pharm Corp | Indazoles, benzotiazoles, benzoisotiazoles, bencisoxazoles y preparacion y usos de los mismos. |
| WO2007014226A2 (en) * | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Compounds for the treatment of neurodegeneration and stroke |
| AU2007208109B2 (en) * | 2006-01-24 | 2012-08-23 | Eli Lilly And Company | Indole sulfonamide modulators of progesterone receptors |
| CN101405001A (zh) | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| JP2011500684A (ja) | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ，インコーポレイティド | ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物 |
| WO2010007944A1 (ja) * | 2008-07-17 | 2010-01-21 | 旭化成ファーマ株式会社 | 含窒素二環性複素環化合物 |
| CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
| AU2011205485B2 (en) | 2010-01-13 | 2014-09-25 | Glaxosmithkline Llc | Compounds and methods |
| JP5864546B2 (ja) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| JP2013526484A (ja) | 2010-05-07 | 2013-06-24 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのアミノ‐キノリン |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| US8623889B2 (en) | 2010-12-17 | 2014-01-07 | Genentech, Inc. | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| EP2471363A1 (de) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen |
| EP2714688B1 (en) | 2011-05-26 | 2016-02-24 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| CN105209031A (zh) | 2012-12-27 | 2015-12-30 | 德雷克塞尔大学 | 针对hbv感染的新型抗病毒剂 |
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| CA3043203A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| EP3947351A4 (en) | 2019-03-29 | 2022-12-07 | Board of Regents, The University of Texas System | SMALL MOLECULAR PARG INHIBITORS AND METHODS OF USE |
| EP4031249A1 (en) | 2019-09-20 | 2022-07-27 | Ideaya Biosciences, Inc. | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| CR20240391A (es) | 2022-03-23 | 2024-11-05 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg |
-
2015
- 2015-12-16 MA MA041179A patent/MA41179A/fr unknown
- 2015-12-17 KR KR1020177019869A patent/KR102682782B1/ko active Active
- 2015-12-17 WO PCT/GB2015/054064 patent/WO2016097749A1/en not_active Ceased
- 2015-12-17 CN CN201580075709.0A patent/CN107295799B/zh active Active
- 2015-12-17 BR BR112017012707-5A patent/BR112017012707B1/pt active IP Right Grant
- 2015-12-17 CN CN202110213641.5A patent/CN112979631B/zh active Active
- 2015-12-17 MX MX2017007976A patent/MX380901B/es unknown
- 2015-12-17 RU RU2017125520A patent/RU2017125520A/ru not_active Application Discontinuation
- 2015-12-17 SG SG11201704843QA patent/SG11201704843QA/en unknown
- 2015-12-17 EP EP15813554.1A patent/EP3233845B1/en active Active
- 2015-12-17 EP EP21179871.5A patent/EP3907224A1/en active Pending
- 2015-12-17 AU AU2015365602A patent/AU2015365602B2/en active Active
- 2015-12-17 US US15/533,819 patent/US10508086B2/en active Active
- 2015-12-17 CA CA2969298A patent/CA2969298C/en active Active
- 2015-12-17 ES ES15813554T patent/ES2886471T3/es active Active
- 2015-12-17 JP JP2017532912A patent/JP6673920B2/ja active Active
-
2017
- 2017-06-07 IL IL252745A patent/IL252745B/en active IP Right Grant
- 2017-06-28 ZA ZA2017/04383A patent/ZA201704383B/en unknown
-
2019
- 2019-10-24 US US16/662,997 patent/US10995073B2/en active Active
-
2021
- 2021-03-17 US US17/204,206 patent/US12129236B2/en active Active
-
2024
- 2024-09-19 US US18/889,613 patent/US20250223266A1/en active Pending